ArticlePloS one2013
Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Comprehensive Insights into Chondroblastoma Metastasis: Metastatic Patterns and Therapeutic Approaches.Cancers · 2024Review
- Development and application of a method to detect 27 respiratory pathogens using multiplex RT-PCR combined with MassARRAY technology.BMC infectious diseases · 2021Article
- Clinical impact of PTEN methylation status as a prognostic marker for breast cancer.Journal, genetic engineering & biotechnology · 2021Article
- PTEN: A Thrifty Gene That Causes Disease in Times of Plenty?Frontiers in nutrition · 2020Article
- Mutation-driven epigenetic alterations as a defining hallmark of central cartilaginous tumours, giant cell tumour of bone and chondroblastoma.Virchows Archiv : an international journal of pathology · 2020Review
- Analysis of PTEN expression and promoter methylation in Uyghur patients with mild type 2 diabetes mellitus.Medicine · 2018Article
- Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy.Frontiers in immunology · 2018Review
- Epigenetic regulation of RTK signaling.Journal of molecular medicine (Berlin, Germany) · 2017Review
- Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Malignant tumors of the uterine corpus: molecular background of their origin.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.Journal of cancer research and clinical oncology · 2015Review
- miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway.The American journal of pathology · 2014Article
- Inactivation of miR-34a by aberrant CpG methylation in Kazakh patients with esophageal carcinoma.Journal of experimental & clinical cancer research : CR · 2014Article
- Morphological Effects of Natural Products on Schizosaccharomyces pombe Measured by Imaging Flow Cytometry.Natural products and bioprospecting · 2014Article
- Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples.Clinical epigenetics · 2014Article
- A novel PTEN gene promoter mutation and untypical Cowden syndrome.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas (STSs) are a rare and fascinating group of diseases that can be subdivided into specific reciprocal translocations in STSs (SRTSs) and nonspecific reciprocal translocations in STSs (NRTSs). PTEN mutations are rare in STSs, suggesting that PTEN expression may be lost by alternative mechanisms such as methylation. In order to reveal whether aberrant PTEN methylation occurs in STSs, MassARRAY Spectrometry was carried to detect methylation patterns of PTEN in STSs. We evaluated methylation levels in 41 CpG sites from -2,515 to -2,186 bp (amplicon A) and -1,786 to -1,416 bp (amplicon B) relative to the translation initiation site in 110 different cases (46 cases of SRTSs, 40 cases of NRTSs, and 24 cases of normal controls). In addition, immunohistochemistry (IHC) was used to detect the loss of PTEN to determine whether PTEN alterations were responsible for decreased PTEN expression. Our data showed that expression of PTEN was diminished in 49 (57%) STSs, whereas the remaining cases (43%) were classified as high expression. Our previous results found that only 2 of 86 cases (2.3%) had a PTEN mutation suggesting that PTEN may be mainly downregulated in STSs by methylation, but not by mutation of PTEN itself. We observed that amplicon A was hypermethylated in STSs with low PTEN expression, whereas normal controls had low methylation levels (P<0.0001), which was not present in amplicon B (P>0.05), nor were there significant differences in the methylation levels in PTEN between SRTS and NRTS cases. The majority of individual CpG units within two amplicons was demonstrated to be hypermethylated. These findings indicate that PTEN hypermethylation is a common event in STSs suggesting that the inactivation of PTEN may be due to hypermethylation in the promoter of PTEN. The aberrant methylation of the CpG sites within PTEN promoter may serve as a potential candidate biomarker for STSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.